THERAPEUTIC DRUG MONITORING OF INFLIXIMAB IN INFLAMMATORY RHEUMATIC DISEASES: REAL-LIFE DATA IN A COHORT OF PATIENTS

被引：0
|
作者：
Martin Lopez, M. [1 ]
Molina Esteban, N. [1 ]
Cabrera, O. [2 ]
Pablos, J. L. [1 ]
机构：
[1] Hosp Univ 12 Octubre, Inst Invest i12, Rheumatol, Madrid, Spain
[2] Hosp Univ 12 Octubre, Immunol, Madrid, Spain
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Spondyloarthritis; bDMARD; Rheumatoid arthritis;
D O I：
10.1136/annrheumdis-2023-eular.4892
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0964
引用
收藏
页码：1700 / 1701
页数：2
相关论文
共 50 条
  • [1] Outcomes of IBD patients treated with infliximab: The impact of therapeutic drug monitoring in real-life clinical practice
    Kamperidis, N.
    Middleton, P.
    Tyrrell, T.
    Stasinos, I.
    Arebi, N.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S394 - S394
  • [2] New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases
    Nemoz, Benjamin
    Ternant, David
    Bailly, Sebastien
    Gautier-Veyret, Elodie
    Jourdil, Jean-Francois
    Bonaz, Bruno
    Stanke-Labesque, Francoise
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (04) : 722 - 728
  • [3] Therapeutic drug monitoring of infliximab biosimilar and anti-infliximab antibodies in inflammatory diseases
    Elberdin, Laida
    Outeda, Maria
    Mateos, Maria
    Martinez, Cristina
    Salvador, Pilar
    Angeles Porta, Maria
    Isabel Martin, Maria
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (01) : 338 - 339
  • [4] The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases
    Chenglong Han
    Josef S Smolen
    Arthur Kavanaugh
    Désirée van der Heijde
    Jürgen Braun
    René Westhovens
    Ning Zhao
    Mahboob U Rahman
    Daniel Baker
    Mohan Bala
    Arthritis Research & Therapy, 9
  • [5] The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases
    Han, Chenglong
    Smolen, Josef S.
    Kavanaugh, Arthur
    Van der Heijde, Desiree
    Braun, Juergen
    Westhovens, Rene
    Zhao, Ning
    Rahman, Mahboob U.
    Baker, Daniel
    Bala, Mohan
    ARTHRITIS RESEARCH & THERAPY, 2007, 9 (05)
  • [6] Therapeutic drug monitoring of infliximab in patients with rheumatic diseases versus optimization of treatments based on clinical response.
    del Pilar, Maria
    Laso, Esther
    Quesada, Alba
    Rebollo, NoemA
    Calvo, M. V.
    PHARMACOTHERAPY, 2016, 36 (07): : E100 - E101
  • [7] Real-life drug persistence in patients with rheumatic diseases treated with CT-P13: a prospective observational cohort study (PERSIST)
    Taylor, Peter C.
    Christensen, Robin
    Moosavi, Shahrzad
    Selema, Pamela
    Guilatco, Ruffy
    Fowler, Heather
    Mueller, Markus
    Liau, Katherine F.
    Haraoui, Boulos
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2021, 5 (02)
  • [8] Therapeutic Drug Monitoring for Dose Optimization of Infliximab in Patients With Inflammatory Bowel Disease: An Analysis of Canadian Real-World Data
    Sealey, David C.
    Ho, Kai Fai
    Zhou, Z. Christina
    Clark, Michael
    Feagan, Brian G.
    Panaccione, Remo
    Steinhart, A. Hillary
    Bolshtyansky, Elena
    Williamson, Martin
    Afif, Waqqas
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2025, 2025 (01)
  • [9] Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting
    Martelli, Laura
    Lopez, Anthony
    Strobel, Sophie
    Danese, Silvio
    Roblin, Xavier
    Baumann, Cedric
    Peyrin-Biroulet, Laurent
    JOURNAL OF DIGESTIVE DISEASES, 2017, 18 (10) : 566 - 573
  • [10] Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases
    Papamichael, Konstantinos
    Clarke, William T.
    Vande Casteele, Niels
    Germansky, Katharine A.
    Feuerstein, Joseph D.
    Melmed, Gil Y.
    Siegel, Corey A.
    Irving, Peter M.
    Cheifetz, Adam S.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (04) : 839 - +
12345